Last reviewed · How we verify
Intravitreal Ranibizumabe
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).
At a glance
| Generic name | Intravitreal Ranibizumabe |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | VEGF-A inhibitor; monoclonal antibody fragment |
| Target | VEGF-A (Vascular Endothelial Growth Factor A) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab binds to and neutralizes VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By inhibiting VEGF-A signaling, it reduces abnormal vessel formation, decreases retinal edema, and slows vision loss in conditions characterized by excessive angiogenesis. The intravitreal route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion (branch and central)
- Diabetic retinopathy
- Myopic choroidal neovascularization
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Ranibizumab for Myopic Neovascularization (PHASE4)
- PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal Ranibizumabe CI brief — competitive landscape report
- Intravitreal Ranibizumabe updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI